AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

New Version Pulmicort Turbuhaler USA Children

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2008-03-24

Last Posted Date: 2011-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 430

Registration Number: NCT00642161

Varicella Vaccination With Pulmicort

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: budesonide
Drug: varicella zoster virus

First Posted Date: 2008-03-24

Last Posted Date: 2009-03-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 250

Registration Number: NCT00641446

A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis

Phase 4

Completed

Conditions: Erosive Esophagitis

Interventions: Drug: Esomeprazole
Drug: Lansoprazole

First Posted Date: 2008-03-24

Last Posted Date: 2009-03-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 1000

Registration Number: NCT00641602

Quetiapine Extended Release Depression Symptoms

Phase 3

Completed

Conditions: Schizophrenia
Depression

Interventions: Drug: Quetiapine Extended Release
Drug: Risperidone

First Posted Date: 2008-03-21

Last Posted Date: 2012-06-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 216

Registration Number: NCT00640562

Locations: 🇮🇹
Research Site, Roma, Italy

Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

First Posted Date: 2008-03-21

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 331

Registration Number: NCT00640601

Locations: 🇰🇷
Research Site, Seoul, Korea, Korea, Republic of

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Exenatide Once Weekly
Drug: Insulin Glargine

First Posted Date: 2008-03-21

Last Posted Date: 2015-06-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 467

Registration Number: NCT00641056

Locations: 🇨🇳
Research Site, Taoyuan, Taiwan

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Drug: Anastrozole

First Posted Date: 2008-03-19

Last Posted Date: 2008-03-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 1600

Registration Number: NCT00638391

Casodex - Nolvadex Combination

Phase 2

Completed

Conditions: Gynaecomastia
Prostate Cancer

Interventions: Drug: Casodex
Drug: Tamoxifen

First Posted Date: 2008-03-18

Last Posted Date: 2011-01-24

Lead Sponsor: AstraZeneca

Registration Number: NCT00637871

Barrett's Esophagus - 315 - 3 Way Cross-Over

Phase 4

Completed

Conditions: Barrett's Esophagus

Interventions: Drug: Esomeprazole Magnesium

First Posted Date: 2008-03-18

Last Posted Date: 2011-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 50

Registration Number: NCT00637559

Barrett's Esophagus - 315 - 3 Way Cross Over

Phase 4

Completed

Conditions: Barrett's Esophagus

Interventions: Drug: Esomeprazole
Drug: Rofecoxib
Drug: Aspirin

First Posted Date: 2008-03-18

Last Posted Date: 2011-01-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT00637988

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy